Protalix BioTherapeutics Issues 2020 Letter to Shareholders
CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant…
Comments Off on Protalix BioTherapeutics Issues 2020 Letter to Shareholders